Download PDF
Semin Neurol 2011; 31(1): 042-053
DOI: 10.1055/s-0031-1271311
© Thieme Medical Publishers

Office Evaluation of the “Tired” or “Sleepy” Patient

Cynthia L. Bodkin1 , Shalini Manchanda2
  • 1Department of Neurology, Critical Care, Allergy and Sleep Medicine, Indiana University School of Medicine, Indianapolis, Indiana
  • 2Department of Pulmonary, Critical Care, Allergy and Sleep Medicine, Indiana University School of Medicine, Indianapolis, Indiana
Further Information

Publication History

Publication Date:
14 February 2011 (online)

    Permissions and Reprints

ABSTRACT

In an outpatient neurologic practice, the patient complaint of being “tired” is frequently encountered yet often not specifically addressed. Clarifying the symptoms and determining whether the tiredness is the result of excessive daytime sleepiness versus fatigue or weakness is the first step in diagnosing and treating the patient. A detailed neurologic and sleep history and exam can often distinguish among these different symptoms, establish the potential causes of excessive sleepiness, and decide on the additional ancillary tests that may be helpful to determine the underlying etiology. Understanding the etiology of patient's symptoms is necessary to initiate appropriate treatment.

KEYWORDS

Excessive daytime sleepiness - hypersomnia - fatigue

REFERENCES

  • 1 The International Classification of Sleep Disorders .Diagnostic and Coding Manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005
    Google Scholar
  • 2 Mills R J, Young C A. A medical definition of fatigue in multiple sclerosis.  QJM. 2008;  101 (1) 49-60
    CrossrefPubMedGoogle Scholar
  • 3 Radbruch L, Strasser F, Elsner F Research Steering Committee of the European Association for Palliative Care (EAPC) et al. Fatigue in palliative care patients — an EAPC approach.  Palliat Med. 2008;  22 (1) 13-32
    CrossrefPubMedGoogle Scholar
  • 4 Dobkin B H. Fatigue versus activity-dependent fatigability in patients with central or peripheral motor impairments.  Neurorehabil Neural Repair. 2008;  22 (2) 105-110
    PubMedGoogle Scholar
  • 5 Lerdal A, Bakken L N, Kouwenhoven S E et al.. Poststroke fatigue—a review.  J Pain Symptom Manage. 2009;  38 (6) 928-949
    CrossrefPubMedGoogle Scholar
  • 6 Multiple Sclerosis Council for Clinical Practice Guidelines .Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC: Paralyzed Veterans of America; 1998
    Google Scholar
  • 7 Hoddes E, Zarcone V, Smythe H, Phillips R, Dement W C. Quantification of sleepiness: a new approach.  Psychophysiology. 1973;  10 (4) 431-436
    CrossrefPubMedGoogle Scholar
  • 8 Johns M W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale.  Sleep. 1991;  14 (6) 540-545
    Google Scholar
  • 9 Chervin R D, Aldrich M S, Pickett R, Guilleminault C. Comparison of the results of the Epworth Sleepiness Scale and the Multiple Sleep Latency Test.  J Psychosom Res. 1997;  42 (2) 145-155
    CrossrefPubMedGoogle Scholar
  • 10 Furuta H, Kaneda R, Kosaka K, Arai H, Sano J, Koshino Y. Epworth Sleepiness Scale and sleep studies in patients with obstructive sleep apnea syndrome.  Psychiatry Clin Neurosci. 1999;  53 (2) 301-302
    CrossrefPubMedGoogle Scholar
  • 11 Benbadis S R, Mascha E, Perry M C, Wolgamuth B R, Smolley L A, Dinner D S. Association between the Epworth sleepiness scale and the multiple sleep latency test in a clinical population.  Ann Intern Med. 1999;  130 (4 Pt 1) 289-292
    PubMedGoogle Scholar
  • 12 Chervin R D, Aldrich M S. The Epworth Sleepiness Scale may not reflect objective measures of sleepiness or sleep apnea.  Neurology. 1999;  52 (1) 125-131
    PubMedGoogle Scholar
  • 13 Krupp L B, LaRocca N G, Muir-Nash J, Steinberg A D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.  Arch Neurol. 1989;  46 (10) 1121-1123
    CrossrefPubMedGoogle Scholar
  • 14 Michielsen H J, De Vries J, Van Heck G L. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale.  J Psychosom Res. 2003;  54 (4) 345-352
    CrossrefPubMedGoogle Scholar
  • 15 Fisk J D, Pontefract A, Ritvo P G, Archibald C J, Murray T J. The impact of fatigue on patients with multiple sclerosis.  Can J Neurol Sci. 1994;  21 (1) 9-14
    CrossrefPubMedGoogle Scholar
  • 16 Mendoza T R, Wang X S, Cleeland C S et al.. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory.  Cancer. 1999;  85 (5) 1186-1196
    CrossrefPubMedGoogle Scholar
  • 17 Fisk J D, Ritvo P G, Ross L, Haase D A, Marrie T J, Schlech W F. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.  Clin Infect Dis. 1994;  18 (Suppl 1) S79-S83
    CrossrefPubMedGoogle Scholar
  • 18 Belza B L. Comparison of self-reported fatigue in rheumatoid arthritis and controls.  J Rheumatol. 1995;  22 (4) 639-643
    PubMedGoogle Scholar
  • 19 Smets E M, Garssen B, Bonke B, De Haes J C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue.  J Psychosom Res. 1995;  39 (3) 315-325
    CrossrefPubMedGoogle Scholar
  • 20 Stein K D, Martin S C, Hann D M, Jacobsen P B. A multidimensional measure of fatigue for use with cancer patients.  Cancer Pract. 1998;  6 (3) 143-152
    CrossrefPubMedGoogle Scholar
  • 21 Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures.  J Pain Symptom Manage. 2009;  37 (1) 107-128
    CrossrefPubMedGoogle Scholar
  • 22 Carskadon M A, Dement W C, Mitler M M, Roth T, Westbrook P R, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness.  Sleep. 1986;  9 (4) 519-524
    PubMedGoogle Scholar
  • 23 Arand D, Bonnet M, Hurwitz T, Mitler M, Rosa R, Sangal R B. The clinical use of the MSLT and MWT.  Sleep. 2005;  28 (1) 123-144
    PubMedGoogle Scholar
  • 24 Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group.  Neurology. 2000;  54 (5) 1166-1175
    CrossrefPubMedGoogle Scholar
  • 25 Singh M, Drake C L, Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample.  Sleep. 2006;  29 (7) 890-895
    PubMedGoogle Scholar
  • 26 Bishop C, Rosenthal L, Helmus T, Roehrs T, Roth T. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness.  Sleep. 1996;  19 (9) 727-730
    PubMedGoogle Scholar
  • 27 Laberge L, Bégin P, Dauvilliers Y et al.. A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1.  J Neurol Neurosurg Psychiatry. 2009;  80 (6) 642-646
    CrossrefPubMedGoogle Scholar
  • 28 Arii J, Kanbayashi T, Tanabe Y, Ono J, Nishino S, Kohno Y. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor.  Neurology. 2001;  56 (12) 1775-1776
    PubMedGoogle Scholar
  • 29 Scammell T E, Nishino S, Mignot E, Saper C B. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke.  Neurology. 2001;  56 (12) 1751-1753
    CrossrefPubMedGoogle Scholar
  • 30 Kato T, Kanbayashi T, Yamamoto K et al.. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions.  Intern Med. 2003;  42 (8) 743-745
    CrossrefPubMedGoogle Scholar
  • 31 Oka Y, Kanbayashi T, Mezaki T et al.. Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis.  J Neurol. 2004;  251 (7) 885-886
    PubMedGoogle Scholar
  • 32 Rubinstein I, Gray T A, Moldofsky H, Hoffstein V. Neurosarcoidosis associated with hypersomnolence treated with corticosteroids and brain irradiation.  Chest. 1988;  94 (1) 205-206
    CrossrefPubMedGoogle Scholar
  • 33 Morgenthaler T, Alessi C, Friedman L Standards of Practice Committee et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007.  Sleep. 2007;  30 (4) 519-529
    CrossrefPubMedGoogle Scholar
  • 34 Nishino S, Ripley B, Overeem S, Lammers G J, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy.  Lancet. 2000;  355 (9197) 39-40
    CrossrefPubMedGoogle Scholar
  • 35 Mignot E, Lin X, Arrigoni J et al.. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans.  Sleep. 1994;  17 (8, Suppl) S60-S67
    PubMedGoogle Scholar
  • 36 Mignot E. Genetic and familial aspects of narcolepsy.  Neurology. 1998;  50 (2, Suppl 1) S16-S22
    CrossrefPubMedGoogle Scholar
  • 37 Avidan A Y. Parasomnias and movement disorders of sleep.  Semin Neurol. 2009;  29 (4) 372-392
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Avidan A Y. Clinical sleep neurology.  Semin Neurol. 2009;  29 (4) 275-276
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Bae C J, Lee J K, Foldvary-Schaefer N. The use of sleep studies in neurologic practice.  Semin Neurol. 2009;  29 (4) 305-319
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Baran A S, Chervin R D. Approach to the patient with sleep complaints.  Semin Neurol. 2009;  29 (4) 297-304
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Brennan K C, Charles A. Sleep and headache.  Semin Neurol. 2009;  29 (4) 406-418
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Chokroverty S. Sleep and neurodegenerative diseases.  Semin Neurol. 2009;  29 (4) 446-467
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Culebras A. Sleep and stroke.  Semin Neurol. 2009;  29 (4) 438-445
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Foldvary-Schaefer N, Grigg-Damberger M. Sleep and epilepsy.  Semin Neurol. 2009;  29 (4) 419-428
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Frenette E, Kushida C A. Primary hypersomnias of central origin.  Semin Neurol. 2009;  29 (4) 354-367
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Goel N, Rao H, Durmer J S, Dinges D F. Neurocognitive consequences of sleep deprivation.  Semin Neurol. 2009;  29 (4) 320-339
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Guilleminault C, Ramar K. Neurologic aspects of sleep apnea: is obstructive sleep apnea a neurologic disorder?.  Semin Neurol. 2009;  29 (4) 368-371
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Neubauer D N, Flaherty K N. Chronic insomnia.  Semin Neurol. 2009;  29 (4) 340-353
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Nicolle M W. Sleep and neuromuscular disease.  Semin Neurol. 2009;  29 (4) 429-437
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Reid K J, Zee P C. Circadian rhythm disorders.  Semin Neurol. 2009;  29 (4) 393-405
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Siegel J M. The neurobiology of sleep.  Semin Neurol. 2009;  29 (4) 277-296
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Ohayon M M, Reynolds III C F. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD).  Sleep Med. 2009;  10 (9) 952-960
    CrossrefPubMedGoogle Scholar
  • 53 Dinges D F, Pack F, Williams K et al.. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4-5 hours per night.  Sleep. 1997;  20 (4) 267-277
    PubMedGoogle Scholar
  • 54 Janjua T, Samp T, Cramer-Bornemann M, Hannon H, Mahowald M W. Clinical caveat: prior sleep deprivation can affect the MSLT for days.  Sleep Med. 2003;  4 (1) 69-72
    CrossrefPubMedGoogle Scholar
  • 55 Marti I, Valko P O, Khatami R, Bassetti C L, Baumann C R. Multiple sleep latency measures in narcolepsy and behaviourally induced insufficient sleep syndrome.  Sleep Med. 2009;  10 (10) 1146-1150
    CrossrefPubMedGoogle Scholar
  • 56 Aeschbach D, Cajochen C, Landolt H, Borbély A A. Homeostatic sleep regulation in habitual short sleepers and long sleepers.  Am J Physiol. 1996;  270 (1 Pt 2) R41-R53
    PubMedGoogle Scholar
  • 57 Hartmann E, Baekeland F, Zwilling G R. Psychological differences between long and short sleepers.  Arch Gen Psychiatry. 1972;  26 (5) 463-468
    CrossrefPubMedGoogle Scholar
  • 58 Young T, Peppard P E, Gottlieb D J. Epidemiology of obstructive sleep apnea: a population health perspective.  Am J Respir Crit Care Med. 2002;  165 (9) 1217-1239
    CrossrefPubMedGoogle Scholar
  • 59 Epstein L J, Kristo D, Strollo Jr P J Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults.  J Clin Sleep Med. 2009;  5 (3) 263-276
    PubMedGoogle Scholar
  • 60 Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lespérance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria.  Mov Disord. 1997;  12 (1) 61-65
    CrossrefPubMedGoogle Scholar
  • 61 Anderson K N, Pilsworth S, Sharples L D, Smith I E, Shneerson J M. Idiopathic hypersomnia: a study of 77 cases.  Sleep. 2007;  30 (10) 1274-1281
    PubMedGoogle Scholar
  • 62 Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy.  Clin Neurophysiol. 2003;  114 (11) 2000-2017
    CrossrefPubMedGoogle Scholar
  • 63 Overeem S, Mignot E, van Dijk J G, Lammers G J. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives.  J Clin Neurophysiol. 2001;  18 (2) 78-105
    CrossrefPubMedGoogle Scholar
  • 64 Kanbayashi T, Inoue Y, Chiba S et al.. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.  J Sleep Res. 2002;  11 (1) 91-93
    CrossrefPubMedGoogle Scholar
  • 65 Mignot E, Lammers G J, Ripley B et al.. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.  Arch Neurol. 2002;  59 (10) 1553-1562
    CrossrefPubMedGoogle Scholar
  • 66 Mayer G, Leonhard E, Krieg J, Meier-Ewert K. Endocrinological and polysomnographic findings in Kleine-Levin syndrome: no evidence for hypothalamic and circadian dysfunction.  Sleep. 1998;  21 (3) 278-284
    PubMedGoogle Scholar
  • 67 Morgenthaler T I, Kapur V K, Brown T Standards of Practice Committee of the American Academy of Sleep Medicine et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.  Sleep. 2007;  30 (12) 1705-1711
    PubMedGoogle Scholar
  • 68 Huck N O, McBride S A, Kendall A P, Grugle N L, Killgore W D. The effects of modafinil, caffeine, and dextroamphetamine on judgments of simple versus complex emotional expressions following sleep deprivation.  Int J Neurosci. 2008;  118 (4) 487-502
    CrossrefPubMedGoogle Scholar
  • 69 Killgore W D, Grugle N L, Killgore D B et al.. Restoration of risk-propensity during sleep deprivation: caffeine, dextroamphetamine, and modafinil.  Aviat Space Environ Med. 2008;  79 (9) 867-874
    CrossrefPubMedGoogle Scholar
  • 70 Killgore W D, Kahn-Greene E T, Grugle N L, Killgore D B, Balkin T J. Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil.  Sleep. 2009;  32 (2) 205-216
    Google Scholar
  • 71 Killgore W D, Rupp T L, Grugle N L, Reichardt R M, Lipizzi E L, Balkin T J. Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness.  J Sleep Res. 2008;  17 (3) 309-321
    CrossrefPubMedGoogle Scholar
  • 72 Wesensten N J, Killgore W D, Balkin T J. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation.  J Sleep Res. 2005;  14 (3) 255-266
    Google Scholar
  • 73 Roth T, Schwartz J R, Hirshkowitz M, Erman M K, Dayno J M, Arora S. Evaluation of the safety of modafinil for treatment of excessive sleepiness.  J Clin Sleep Med. 2007;  3 (6) 595-602
    PubMedGoogle Scholar
  • 74 Orlikowski D, Chevret S, Quera-Salva M A et al.. Modafinil for the treatment of hypersomnia associated with myotonic muscular dystrophy in adults: a multicenter, prospective, randomized, double-blind, placebo-controlled, 4-week trial.  Clin Ther. 2009;  31 (8) 1765-1773
    CrossrefPubMedGoogle Scholar
  • 75 Damian M S, Gerlach A, Schmidt F, Lehmann E, Reichmann H. Modafinil for excessive daytime sleepiness in myotonic dystrophy.  Neurology. 2001;  56 (6) 794-796
    CrossrefPubMedGoogle Scholar
  • 76 MacDonald J R, Hill J D, Tarnopolsky M A. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy.  Neurology. 2002;  59 (12) 1876-1880
    CrossrefPubMedGoogle Scholar
  • 77 Talbot K, Stradling J, Crosby J, Hilton-Jones D. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.  Neuromuscul Disord. 2003;  13 (5) 357-364
    CrossrefPubMedGoogle Scholar
  • 78 Wintzen A R, Lammers G J, van Dijk J G. Does modafinil enhance activity of patients with myotonic dystrophy?: a double-blind placebo-controlled crossover study.  J Neurol. 2007;  254 (1) 26-28
    CrossrefPubMedGoogle Scholar
  • 79 Adler C H, Caviness J N, Hentz J G, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.  Mov Disord. 2003;  18 (3) 287-293
    CrossrefPubMedGoogle Scholar
  • 80 Ondo W G, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.  J Neurol Neurosurg Psychiatry. 2005;  76 (12) 1636-1639
    CrossrefPubMedGoogle Scholar
  • 81 Darwish M, Kirby M, Hellriegel E T, Robertson Jr P. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies.  Clin Drug Investig. 2009;  29 (9) 613-623
    PubMedGoogle Scholar
  • 82 Darwish M, Kirby M, Hellriegel E T. Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects.  Clin Drug Investig. 2009;  29 (9) 601-612
    PubMedGoogle Scholar
  • 83 Jha A, Weintraub A, Allshouse A et al.. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury.  J Head Trauma Rehabil. 2008;  23 (1) 52-63
    CrossrefPubMedGoogle Scholar
  • 84 Brioschi A, Gramigna S, Werth E et al.. Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients.  Eur Neurol. 2009;  62 (4) 243-249
    CrossrefPubMedGoogle Scholar
  • 85 Rammohan K W, Rosenberg J H, Lynn D J, Blumenfeld A M, Pollak C P, Nagaraja H N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.  J Neurol Neurosurg Psychiatry. 2002;  72 (2) 179-183
    CrossrefPubMedGoogle Scholar
  • 86 Stankoff B, Waubant E, Confavreux C French Modafinil Study Group et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.  Neurology. 2005;  64 (7) 1139-1143
    CrossrefPubMedGoogle Scholar
  • 87 Vasconcelos O M, Prokhorenko O A, Salajegheh M K et al.. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial.  Neurology. 2007;  68 (20) 1680-1686
    CrossrefPubMedGoogle Scholar
  • 88 Chan K M, Strohschein F J, Rydz D, Allidina A, Shuaib A, Westbury C F. Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients.  Muscle Nerve. 2006;  33 (1) 138-141
    CrossrefPubMedGoogle Scholar
  • 89 Rabkin J G, Gordon P H, McElhiney M, Rabkin R, Chew S, Mitsumoto H. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study.  Muscle Nerve. 2009;  39 (3) 297-303
    CrossrefPubMedGoogle Scholar
  • 90 Kumar R. Approved and investigational uses of modafinil: an evidence-based review.  Drugs. 2008;  68 (13) 1803-1839
    CrossrefPubMedGoogle Scholar
  • 91 The Canadian MS Research Group . A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis.  Can J Neurol Sci. 1987;  14 (3) 273-278
    PubMedGoogle Scholar
  • 92 Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue.  J Neurol. 2009;  256 (4) 645-650
    CrossrefPubMedGoogle Scholar
  • 93 Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis.  Cochrane Database Syst Rev. 2007;  (1) CD002818
    PubMedGoogle Scholar
  • 94 McGeough E, Pollock A, Smith L N et al.. Interventions for post-stroke fatigue.  Cochrane Database Syst Rev. 2009;  (3) CD007030
    PubMedGoogle Scholar
  • 95 Malouff J M, Thorsteinsson E B, Rooke S E, Bhullar N, Schutte N S. Efficacy of cognitive behavioral therapy for chronic fatigue syndrome: a meta-analysis.  Clin Psychol Rev. 2008;  28 (5) 736-745
    CrossrefPubMedGoogle Scholar
  • 96 Edmonds M, McGuire H, Price J. Exercise therapy for chronic fatigue syndrome.  Cochrane Database Syst Rev. 2004;  (3) CD003200
    PubMedGoogle Scholar

Cynthia L BodkinM.D. 

550 University Blvd.

Rm. 1710, Indianapolis, IN 46202

Email: Cbodkin@iupui.edu

      >